Dose Escalation:
Trametinib 2mg daily monotherapy for 14 days. Followed by combination oral trametinb (2mg starting dose) daily and oral ruxolitinib (5mg starting dose) twice daily at assigned doses.
Dose Expansion:
Trametinib 2mg daily monotherapy for 14 days. Followed by combination oral trametinb daily and oral ruxolitinib twice daily at the maximum tolerated dose (MTD) established at the Dose Escalation phase.
A cycle of therapy will comprise of 28 days of combination trametinib and ruxolitinib treatment.

Colorectal Cancer

Pancreatic Adenocarcinoma

Trametinib

Ruxolitinib

National Cancer Centre

Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

Phase Ib Study Evaluating Safety and Tolerability of Combination Trametinib and Ruxolitinib in Patients With Advanced RAS Mutant Colorectal Cancer and Pancreatic Adenocarcinoma

Highest dose level at which less than one-third of the patients in the dose level experienced dose limiting toxicities (DLTs) during the first cycle of treatment

To assess the safety of the drug combination. During the dose escalation phase, this includes the incidences of dose limiting toxicities during the first 2 cycles of treatment.

Unit of measure: g/dL. To assess the safety of the drug combination

Unit of measure: x 10^9/L. To assess the safety of the drug combination.

Unit of measure: Percentage component of white blood cells. To assess the safety of the drug combination.

Unit of measure: mmol/L. To assess the safety of the drug combination

Unit of measure: umol/L. To assess the safety of the drug combination

Unit of measure: g/L. To assess the safety of the drug combination

Unit of measure: U/L. To assess the safety of the drug combination

To assess the tolerability of the drug combination.

To assess the tolerability of the drug combination

Trough concentrations of trametinb at different cycles of combination treatment with ruxolitinib

Changes from baseline tumour markers (CEA and CA 19-9) in blood samples

The best overall response is the best response recorded from the start of the treatment until disease progression (PD)/ recurrence (taking as reference for PD the smallest measurements recorded since the treatment started).

Percentage of patients who have achieved complete response, partial response and stable disease in accordance to RECIST 1.1.

Time elapsed between treatment initiation and tumour progression or death from any cause, with censoring of patients who are lost to follow-up.

Time elapsed between treatment initiation and death from any cause, with censoring of patients who are lost to follow-up.

National Cancer Centre, Singapore

The first part of this study will be a standard 3+3 dose-escalating

Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL

Participants with relapsed/ refractory Mantle Cell Lymphoma (MCL)

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Ibrutinib

200mg IV pembrolizumab on Day 1 of each cycle

Pembrolizumab

Icahn School of Medicine at Mount Sinai

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

Safety of fixed dose as determined by DLT to determine recommended phase 2 dosing

Number of participants with complete response to combination ibrutinib/pembrolizumab therapy in Phase 2

Phase 2: Number of participants with progression-free disease

Phase 2: Number of Participants alive at 1 year of combination therapy

Joshua Brody

Assistant Professor

Merck Sharp & Dohme Corp.

This is a non-randomized trial. Patients will be allocated to appropriate cohort A-D per their disease type and time of enrollment to study.

Basal Cell Carcinoma

No intervention

Hospital Central Dr. Ignacio Morones Prieto

The Role of Melanocyte in Basal Cell Carcinoma

Melanocyte Features and Its Influence in Pigmentation in Basal Cell Carcinoma in the Mexican Population

To quantify the number of melanocytes in basal cell carcinoma

To quantify melanocyte maturation stages in basal cell carcinoma through markers

To quantify the expression of melanogenic markers in basal cell carcinoma

To quantify melanin deposition in basal cell carcinoma using special histologic stains (Fontana-Masson)

To quantify number of vessels in basal cell carcinoma using special histologic stains (Elastic fibers)

To quantify melanocytes in basal cell carcinoma using special histologic stains (Giemsa)

To quantify solar elastosis in basal cell carcinoma using special histologic stains (Elastic fibers)

Juan Pablo Castanedo-Cazares

Study Director

Universidad Autonoma de San Luis Potosí

Hospital Central "Dr. Ignacio Morones Prieto"

Topotecan and pazopanib are administered orallydaily

Glioblastoma

Glioblastoma Multiforme

Gliosarcoma

Brain Neoplasms

Central Nervous System Neoplasms

Taken .25 mg orally, daily continuous until progression up to one year.

topotecan

600 mg orally, daily until progression, up to one year.

pazopanib

National Institutes of Health Clinical Center, 9000 Rockville Pike

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Proportion of patients that have progressive disease after 3 months and 6 months.

skin neoplasms/tyrosine

Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

The Role of Melanocyte in Basal Cell Carcinoma

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

科學支持的最完整的草藥數據庫